Made-in-India CURAPOD becomes first wearable Class II device for musculoskeletal pain to receive CDSCO approval

Hyderabad, December 17: CURAPOD, a Made-in-India health-tech brand backed by Litemed India, has received approval from the Central Drugs Standard Control Organization for its wearable musculoskeletal pain management device, marking a first for a non-invasive personalised pain relief wearable in the Class II medical device category in India.

The device is also registered with the US Food and Drug Administration and has been clinically validated through multicentre trials. Designed to address more than 30 musculoskeletal conditions—including chronic back and knee pain, arthritis, tendonitis and sports injuries—CURAPOD offers drug-free pain relief, often delivering noticeable comfort within 30 minutes of use.

CURAPOD uses medical-grade photobiomodulation technology, delivering red and near-infrared light to promote cellular repair, reduce inflammation and accelerate recovery. An adaptive engine calibrates therapy intensity in real time based on muscle response, while a companion mobile application enables personalised therapy plans, progress tracking and pain monitoring.

“CURAPOD’s adaptive system adjusts intensity based on user comfort, offering consistent and targeted pain relief,” said Surya Maguluri, founder and Chief Technology Officer of CURAPOD. He said the data-driven design allows clinicians to remotely monitor outcomes and refine therapy protocols, bridging clinical precision with everyday usability.

Priced at ₹8,399, the wearable is positioned as a professional-grade yet consumer-accessible therapy solution. The device is currently available pan-India through CURAPOD’s direct-to-consumer platform and is slated to be listed on leading online marketplaces from the first quarter of 2026. The company plans wider retail and e-commerce expansion over the next two years.

Sri Velliyur, co-founder and Chief Executive Officer of CURAPOD, said the company has focused on building trust, accessibility and reliability by manufacturing entirely in India and partnering with physiotherapy centres and wellness networks, including in tier-2 and tier-3 cities. He added that the goal is to make clinically validated, non-invasive pain relief widely accessible without compromising quality or affordability.

Founded in 2022, CURAPOD develops personalised, drug-free pain management solutions using proprietary adaptive technology and medical-grade photobiomodulation. The company’s devices are engineered and manufactured in India and distributed through a digital-first model supported by clinical partnerships, aligning local innovation with global regulatory and clinical standards.